The Management Team

About us - Liz Portrait (200 x 200)

Elizabeth (Liz) Thomas FRSC

Co-Founder, Board Member and CEO

Liz has been working in the CRO and Pharmaceutical industries for over 25 years.

In 2011 she joined ICON as Vice President and General Manager of the EU Bioanalytical Business with a major role in the harmonization and development of the bioanalytical business globally.  Prior to joining ICON, Liz was the Global Discipline Leader for Bioanalysis and local Section Director for Bioanalysis and Biomarkers in the Clinical Pharmacology and DMPK function in AstraZeneca.  In this role she was responsible for providing scientific, regulatory and strategic leadership globally and locally.  Prior to joining AstraZeneca in 2001 she managed bioanalytical groups in Quintiles and Covance.

Liz is well known throughout the pharmaceutical and CRO industries.  She has represented both ICON and AstraZeneca on the European Bioanalysis Forum (EBF) and is a member of a Global Bioanalytical Consortium (GBC) harmonisation team.  She has presented on bioanalytical and regulatory topics in the UK, US, China, India and Jordan.

Liz qualified as an Analytical Chemist while working at Glasgow University and is a Fellow of the Royal Society of Chemistry (FRSC).  

linkedin (50 x 50) Link-in with Liz

Email Liz:  elizabeth.thomas@alderleyanalytical.com

.                

.About us - Paul Portrait (200 x 200)

Paul Holme BSc (Hons) MRQA

Co-Founder, Board Member and Director of Operations

Paul has been working in the CRO and pharmaceutical industries for over 25 years.  He has experience in toxicology, skin penetration, metabolism and bioanalysis in both discovery and regulatory environments.  Paul has extensive experience of developing and running LC-MS/MS, GC-MS/MS, HPLC-UV and ICP analytical methods.

Paul started his career in 1989 within ICI directing studies in toxicology and DMPK functions.  It was during this time that he got the opportunity to lead the design and build of a new bioanalytical unit.   In 2003, he moved to AstraZeneca and soon became the Group Manager of the Regulatory Bioanalysis Unit at Alderley Park.  In 2011, he was promoted to the role of Associate Director of In-vivo Pharmacokinetics and Bioanalysis within AstraZeneca.  Paul successfully led global change and harmonisation teams helping mould AstraZeneca’s future strategies.

More recently, he took a senior position in a small CRO conducting regulatory skin penetration studies which provided the valuable insight into running a small company.

Paul is recognised as an experienced scientist and a motivational leader, adept at building and managing high performing teams and for maximising efficiency and productivity.  He obtained his degree at Manchester Metropolitan University, holds a Prince II Practitioner certification and due to his extensive experience in GLP and GCP regulated departments he has recently been accepted as a Member of the Research Quality Association (MRQA).

linkedin (50 x 50) Link-in with Paul

Email Paul:  paul.holme@alderleyanalytical.com

 

About us - Claire Portrait (200 x 200)

Claire Wildgoose BSc (Hons)

Co-Founder and Director of Projects

Claire has worked in the CRO industry for over 21 years.

Until December 2013 she was a Bioanalytical Project Manager at ICON, where she managed small molecule, large molecule and biomarker projects.

Claire started her career as a laboratory scientist at Medeval and has approximately six years’ experience working as a bench top scientist.  In 1999 she moved into the project management team in the role of Project Leader, working on GLP, GCP and discovery projects.   In 2002 Medeval was acquired by ICON and it was with ICON that she continued to develop her project management career.

Claire has an excellent customer focus and a proven track record of delivering high quality results on time to GLP/GCP regulatory standards, while focusing on cost, time and quality through the life cycle of a project.

Whilst in her project management role at ICON Claire designed and implemented an effective method for the collection and reporting of metrics, and had a key role in both the global harmonisation and continuous improvement teams.

Claire has a first class honours degree in Applied Chemistry from Manchester Metropolitan University.

linkedin (50 x 50) Link-in with Claire

Email Claire: claire.wildgoose@alderleyanalytical.com

 

About us - Sally Portrait (200 x 200)

Sally Hannam BSc MRSC

Co-Founder and Director of Science

Sally has been working in the CRO industry for over 25 years.

Until December 2013 she was an Associate Director at ICON, responsible for the management of a team of LC-MS/MS scientists in the Manchester bioanalytical facility.

She started her career as a sandwich placement student at Medeval in 1986, where she developed and validated her very first bioanalytical method.  She was recruited by Medeval following her graduation and was instrumental in developing quality systems that led to the laboratory gaining GLP accreditation in November 1996. She worked for Medeval in various roles until the company was acquired by ICON in 2002.  She continued to develop her professional career at ICON before forming Alderley Analytical In January 2014 with her Co-Founders.

Sally has extensive bioanalytical experience in small molecules, peptides, biomarkers and novel formulations.  She has been personally involved in the development and validation of over 300 methods to regulatory guidelines and has experience with a variety of extraction techniques and analytical platforms.

Sally has a large and effective network of contacts in the pharmaceutical and biotechnology sector and has collaborated and partnered with customers, as well as scientists from instrument manufacturing companies.

Sally has an honours degree in Applied Biological Sciences and is a Member of the Royal Society of Chemistry (MRSC).

linkedin (50 x 50) Link-in with Sally

Email Sally:  sally.hannam@alderleyanalytical.com

 

 

Glenn Crocker, chief executive of BioCity

Glenn Crocker MBE

Board Member

Glenn has a BSc in Genetics from Nottingham University and a DPhil in Immunology from Oxford University. Following a short time in post-doctoral research he joined Ernst & Young and qualified as a chartered accountant.

During his 12 years at BioCity Nottingham he has grown this ex Boots R&D City Centre site into a profitable business through his innovative approach to business incubation where the focus is on the company and its ability to survive and grow profitably. This approach attracted 96 companies to start life with BioCity and 91% of those companies remain in business and continue to grow.

Glenn was the co-founder of R5 Pharmaceuticals (which was subsequently sold to Aesica) and BioAscent Discovery and has been closely involved in the establishment of Xenogesis and a number of other life science companies.

He has led the expansion of BioCity into Scotland; established collaborations with Boots, a member of Alliance Boots, to create MediCity – the health, beauty and wellness innovation hub; and was appointed by Astra Zeneca to create a BioHub at its Alderley Park site, Cheshire.

BioCity and Glenn have received a number of awards in recognition of these achievements. He is the author of the UK Life Sciences Start-up Report, an annual survey of the UK start up sector and co-founder of the UK Bio-incubation Forum – a leading membership association and independent voice for life science business incubation and accelerated growth, influencing policy at local, national, European and international level.

In June 2014 Glenn was awarded an MBE for services to the Biotechnology Industry.

 

Contact Us